Citius Oncology Inc (CTOR)

Oct 16, 2025

Citius Oncology and EVERSANA sign exclusive agreement for Q4 2025 launch of LYMPHIR - ROI-NJ

Oct 16, 2025

Oct 16, 2025

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Fourth Quarter 2025 Launch of LYMPHIR - MarketScreener

Oct 16, 2025

Oct 16, 2025

Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4 - MarketScreener

Oct 16, 2025

Oct 16, 2025

Citius Oncology signs exclusive commercialization agreement with Eversana to support planned Q4 2025 launch of Lymphir - MarketScreener

Oct 16, 2025

Oct 16, 2025

Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR - TradingView

Oct 16, 2025

Oct 16, 2025

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ - PR Newswire

Oct 16, 2025

Oct 16, 2025

Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch - The Globe and Mail

Oct 16, 2025

Oct 15, 2025

Real time breakdown of Citius Oncology Inc. stock performance2025 Market Overview & Verified High Yield Trade Plans - newser.com

Oct 15, 2025

Oct 15, 2025

How Citius Oncology Inc. stock benefits from tech adoption2025 Sector Review & Accurate Entry/Exit Alerts - newser.com

Oct 15, 2025

Oct 15, 2025

Citius Oncology Inc. stock prediction for this weekJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com

Oct 15, 2025

Oct 14, 2025

What analysts say about Citius Oncology Inc stockCurrency Fluctuation Impact & High Return Wealth Building - earlytimes.in

Oct 14, 2025

Oct 14, 2025

Why Citius Oncology Inc. stock is recommended by analysts2025 Analyst Calls & Reliable Trade Execution Plans - newser.com

Oct 14, 2025

Oct 14, 2025

Sector ETF performance correlation with Citius Oncology Inc.Trade Analysis Summary & Short-Term High Return Strategies - newser.com

Oct 14, 2025

Oct 13, 2025

What to do if you’re stuck in Citius Oncology Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews

Oct 13, 2025

Oct 13, 2025

Is Citius Oncology Inc. stock attractive for long term wealth buildingBuy Signal & Fast Moving Stock Watchlists - newser.com

Oct 13, 2025

Oct 12, 2025

Is Citius Oncology Inc. stock bottoming out2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com

Oct 12, 2025

Oct 12, 2025

Is it too late to sell Citius Oncology Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com

Oct 12, 2025

Oct 10, 2025

Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Heatmap analysis for Citius Oncology Inc. and competitors2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 09, 2025

How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com

Oct 09, 2025

Oct 09, 2025

Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com

Oct 09, 2025

Oct 09, 2025

Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com

Oct 09, 2025

Oct 09, 2025

Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com

Oct 09, 2025

Oct 08, 2025

Citius in talks over Lymphir access in global markets - The Pharma Letter

Oct 08, 2025

Oct 08, 2025

Citius Oncology expands LYMPHIR access through named patient programs By Investing.com - Investing.com Canada

Oct 08, 2025

Oct 07, 2025

Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener

Oct 07, 2025

Oct 07, 2025

Citius Oncology expands LYMPHIR access through named patient programs - Investing.com

Oct 07, 2025

Oct 07, 2025

Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener

Oct 07, 2025

Oct 07, 2025

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire

Oct 07, 2025

Oct 06, 2025

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World

Oct 06, 2025

Oct 05, 2025

Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com

Oct 05, 2025

Oct 05, 2025

Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com

Oct 05, 2025

Oct 05, 2025

Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com

Oct 05, 2025

Oct 05, 2025

What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com

Oct 05, 2025

Oct 03, 2025

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat

Oct 03, 2025

Oct 03, 2025

Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World

Oct 03, 2025